{"id":2196,"date":"2026-07-27T09:15:00","date_gmt":"2026-07-27T13:15:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2196"},"modified":"2026-07-27T20:01:04","modified_gmt":"2026-07-28T00:01:04","slug":"hdac6-links-b-all-motility-to-relapse","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2196","title":{"rendered":"HDAC6 Links B-ALL Motility to Relapse"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

CINVESTAV (Center for Research and Advanced Studies of the National Polytechnic Institute)<\/p>\n

Event Type<\/strong><\/p>\n

Preclinical Research Findings<\/p>\n

Modality<\/strong><\/p>\n

Small-molecule \/ genetic target validation (HDAC6 inhibition)<\/p>\n

Asset<\/strong><\/p>\n

HDAC6-selective chemistry (research-stage, not a named clinical asset)<\/p>\n

Target<\/strong><\/p>\n

HDAC6 (via cortactin-dependent cytoskeletal remodeling)<\/p>\n

Disease Area<\/strong><\/p>\n

B-cell Acute Lymphoblastic Leukemia (B-ALL)<\/p>\n

Summary<\/h4>\n

A July 26 British Journal of Cancer study linked elevated HDAC6 expression with relapse in pediatric and adult B-ALL cohorts and showed that pharmacologic inhibition or shRNA depletion reduced CXCL12-driven actin remodeling, endothelial migration, marrow colonization, and leukemic dissemination. Cortactin-depletion experiments supported pathway dependence. The combined clinical and functional evidence identifies HDAC6 as a biomarker and therapeutic hypothesis, but it does not demonstrate that an HDAC6 inhibitor improves leukemia control or survival in patients.<\/p>\n

HDAC6 expression was assessed in 72 pediatric and 54 adult B-ALL patients and in leukemia cell lines.<\/p>\n

Higher expression was significantly associated with relapse in both clinical cohorts.<\/p>\n

Pharmacologic inhibition and genetic knockdown impaired CXCL12-induced cytoskeletal remodeling, transendothelial migration, marrow colonization, and in-vivo dissemination.<\/p>\n

HDAC6 inhibition did not further reduce migration in cortactin-deficient cells, supporting an HDAC6\u2013cortactin mechanism.<\/p>\n

Mechanistic interpretation<\/h4>\n

HDAC6 is a cytoplasmic deacetylase that regulates cortactin and actin dynamics. The study connects this machinery to niche trafficking rather than only leukemia-cell proliferation.<\/p>\n

Blocking dissemination could complement cytotoxic or immune therapy, but residual disease may persist if survival pathways remain intact.<\/p>\n

Alternative interpretations and validation gate<\/h4>\n

Interpretation A is that HDAC6 drives relapse through marrow and tissue trafficking. Concordant clinical association and pathway experiments support this.<\/p>\n

Interpretation B is that HDAC6 is a marker of aggressive cell state rather than a therapeutically dominant driver. Nonrandom patient data and model dependence support this concern.<\/p>\n

Prospective biomarker validation, selective-inhibitor pharmacology, combination studies, patient-derived xenografts, and clinical MRD\/relapse outcomes would upgrade or falsify target relevance.<\/p>\n

Development implications<\/h4>\n

Existing HDAC6-selective chemistry could accelerate translational testing, although exposure, selectivity, neuropathy, cytopenia, and combination tolerability require scrutiny.<\/p>\n

A biomarker-led strategy should distinguish expression, enzymatic activity, and cortactin acetylation rather than rely on a single assay.<\/p>\n

Evidence limitations<\/h4>\n

The patient cohorts are modest and observational. Treatment heterogeneity and subtype distribution may confound relapse association.<\/p>\n

Preclinical migration and dissemination endpoints are not equivalent to patient survival or cure.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Rolling-gap publication catch-up: peer-reviewed article published July 26.<\/li>\n
  • Core B-ALL biology: relapse-associated trafficking mechanism.<\/li>\n
  • Orthogonal validation: two patient cohorts, pharmacology, knockdown, and cortactin epistasis.<\/li>\n
  • Potential repurposing path through existing HDAC6-selective compounds.<\/li>\n
  • No clinical intervention data.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The study elevates HDAC6 from a correlation to a mechanistically supported dissemination target, but clinical direction remains uncertain.<\/p>\n

    The most informative next step is biomarker-selected combination testing that measures marrow persistence and relapse, not only migration.<\/p>\n

    Company and Product Background<\/h4>\n

    B-ALL is a precursor B-cell malignancy in which residual marrow disease and tissue dissemination contribute to relapse.<\/p>\n

    HDAC6 deacetylates cytoplasmic substrates including cortactin, regulating actin remodeling, chemotaxis, and transendothelial migration.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 3\/5 \u2014 Medium-High. Importance:<\/strong> Moderate \u2014 the work identifies a relapse-linked, potentially druggable trafficking mechanism in B-ALL, though it does not yet demonstrate clinical efficacy. Confidence:<\/strong> High on facts, Medium on interpretation \u2014 peer-reviewed clinical associations and orthogonal functional experiments are solid, but driver status and therapeutic window remain unproven.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A July 26 British Journal of Cancer study linked elevated HDAC6 expression with relapse in pediatric and adult B-ALL cohorts and showed that pharmacologic inhibition or shRNA depletion reduced CXCL12-driven actin remodeling, endothelial migration,…<\/p>\n","protected":false},"author":1,"featured_media":2205,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[202,201],"class_list":["post-2196","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-b-cell-acute-lymphoblastic-leukemia","tag-cinvestav"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2196"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2196\/revisions"}],"predecessor-version":[{"id":2213,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2196\/revisions\/2213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2205"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}